Ropeginterferon is a long-acting next-generation mono-pegylated interferon alfa-2b consisting of one isoform produced by PharmaEssentia Co. and the pegylated (PEG) formulations that require less frequent administration and have improved efficacy and tolerability.
In this study, patients in the investigational arm will receive Ropeginterferon subcutaneously with 250 g at week 0, 350 g at week 2, 500 g at week 4, and thereafter 500 g bi-weekly until week 24.